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Abstract
A number of antiepileptic medications that modulate GABAA mediated synaptic transmission are anxiolytic. The loop
diuretics furosemide (Lasix) and bumetanide (Bumex) are thought to have antiepileptic properties. These drugs also
modulate GABAA mediated signalling through their antagonism of cation-chloride cotransporters. Given that loop diuretics
may act as antiepileptic drugs that modulate GABAergic signalling, we sought to investigate whether they also mediate
anxiolytic effects. Here we report the first investigation of the anxiolytic effects of these drugs in rat models of anxiety.
Furosemide and bumetanide were tested in adult rats for their anxiolytic effects using four standard anxiety models: 1)
contextual fear conditioning; 2) fear-potentiated startle; 3) elevated plus maze, and 4) open-field test. Furosemide and
bumetanide significantly reduced conditioned anxiety in the contextual fear-conditioning and fear-potentiated startle
models. At the tested doses, neither compound had significant anxiolytic effects on unconditioned anxiety in the elevated
plus maze and open-field test models. These observations suggest that loop diuretics elicit significant anxiolytic effects in
rat models of conditioned anxiety. Since loop diuretics are antagonists of the NKCC1 and KCC2 cotransporters, these results
implicate the cation-chloride cotransport system as possible molecular mechanism involved in anxiety, and as novel
pharmacological target for the development of anxiolytics. In view of these findings, and since furosemide and bumetanide
are safe and well tolerated drugs, the clinical potential of loop diuretics for treating some types of anxiety disorders
deserves further investigation.
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Introduction
Anxiety disorders are the most prevalent class of psychiatric
conditions, affecting approximately 18% of adults [1–3]. These
disorders include Panic Disorder (PD), Social Anxiety Disorder
(SAD), Obsessive Compulsive Disorder (OCD), Posttraumatic
Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD),
and Specific Phobia [4]. Medications currently used for treating
these disorders include tricyclic antidepressants, selective serotonin
reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake
inhibitors (SNRIs), benzodiazepines, anticonvulsants, and mono-
amine oxidase inhibitors. However, 20%–40% of anxiety patients
remain non-responders to all available therapies [5]. Additionally,
many of the anxiolytic medications can elicit central nervous
system (CNS) side-effects that patients find difficult to tolerate
[5,6]. There is a need for new pharmacotherapeutic approaches to
treat anxiety with greater efficacy and fewer side effects.
c-aminobutyric acid (GABA)is the primary inhibitory neuro-
transmitter in the CNS. The downregulation of GABAA inhibition
in the brain has been hypothesized to contribute to pathophys-
iological anxiety [7]. Antiepileptic drugs that enhance GABAA
signaling often possess anxiolytic properties and are commonly
prescribed to treat anxiety. These drugs include pregabalin for
GAD, pregabalin and gabapentin for SAD, and a number of
benzodiazepines for GAD, SAD, and panic disorder [8]. The loop
diuretics furosemide (Lasix) and bumetanide (Bumex) are also
thought to be GABAA modulators with antiepileptic properties [9–
12]. These drugs have attracted some interest from epilepsy
researchers because of their antiepileptic effects over a wide variety
of experimental seizure models [9,11,13,14], and several clinical
findings suggesting they can suppress seizures in patients with
medically intractable epilepsy [15,16].
Loop diuretics are thought to affect GABAA dependent
signaling in the brain through their antagonism of cation-chloride
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from all other known pharmacological GABAA modulators [17].
Specifically, furosemide and bumetanide antagonize the Na
+-K
+-
2Cl
2 (NKCC1) cotransporter that is present on both neurons and
glial cells, and the neuron-specific K
+-Cl
2 (KCC2) cotransporter
[10,11,18–20]. NKCC1 normally transports chloride from the
extracellular to intracellular spaces, and KCC2 transports chloride
from intracellular to extracellular spaces. Although furosemide
and bumetanide are thought to antagonize both cotransporters,
they both have significantly greater affinity for NKCC1 over
KCC2 [10]. Hyperpolarizing inhibitory postsynaptic potentials in
neurons are generated by the influx of anions (HCO3
2 and Cl
2)
down their electrochemical gradients [21]. Since GABAA
receptor-mediated current is determined, in part, by the difference
between the equilibrium potential for Cl
2 and the neuronal
membrane potential [22], preferential antagonism of NKCC1
with a loop diuretic would be expected to cause a hyperpolarizing
shift in the GABA reversal potential, enhancing GABAA synaptic
signalling. This effect can be particularly important in view of
recent work showing the dominant role that NKCC1 plays at the
axon initial segment of principal neurons [23,24].
Given that loop diuretics possibly act as antiepileptic agents that
enhance GABAA inhibition, we sought to investigate whether they
also mediate anxiolytic effects. Towards that end, we tested the
anxiolytic effects of furosemide (100 mg/kg I.V.) and bumetanide
(70 mg/kg I.V.), on four standard rat anxiety models: 1)
Contextual Fear-Conditioning which measures fear, in terms of
freezing, linked to a context where footshock occurred [25,26]; 2)
Fear-Potentiated Startle which measures conditioned fear in terms
of the increase in the startle reflex elicited by sudden noise in the
presence of a cue that was previously paired with footshock
[27,28]; 3) Elevated Plus Maze which assesses unconditioned fear
in terms of the degree to which rats explore regions that normally
elicit their fear of heights and lighted un-enclosed spaces [29]; and
4) Open-Field Test, which assesses unconditioned fear in terms of
the degree to which rats’ innate fear of a novel and well-lit open
field impedes their desire to explore new environments [30]. The
doses of the furosemide and bumetanide were chosen to be similar
to those previously shown to suppress kainic acid induced seizures
in adult rats [9,31].
Results
Contextual Fear-Conditioning
The rats treated with bumetanide (N=8) and furosemide
(N=8) spent a significantly smaller percentage of the test period
freezing compared to the rats treated with vehicle alone (N=8)
(vehicle mean=66.914 [SE=7.04]; bumetanide mean=24.3
[SE=6.80]; furosemide mean=30.12 [SE=4.91]) (df=2;
F=13.382; p,0.0001) (see Figure 1).
Fear-Potentiated Startle
The rats treated with bumetanide (N=8) and furosemide
(N=7) had significantly less increase in startle amplitude with the
shock-conditioned stimulus than rats treated with vehicle alone
(N=8) (vehicle mean=78.22 [SE=21.10]; bumetanide
mean=28.75 [SE=13.03]; furosemide mean=28.42
[SE=10.82]) (df=2; F=9.99; p,0.001) (see Figure 2).
Elevated Plus Maze
No significant differences were seen for rats treated with
bumetanide (N=8) and furosemide (N=8) compared with those
treated with vehicle alone (N=8) on entries into closed arms, time
spentintheopen,andtripstoatleastthemidpointofopenarms(see
Table 1).
Open-Field Test
No significant differences were seen for rats treated with
bumetanide (N=8) and furosemide (N=8) compared with those
treated with vehicle alone (N=8) on the total distance travelled in
the open-field, total time spent moving in the open-field, number
of rears, time spent rearing, distance travelled within the margin of
the field, time spent within the margin of the field, distance
travelled within the center of the open-field, and time spent within
the center of the open-field (see Table 2).
Discussion
The findings of this study suggest that, at the doses tested,
furosemide and bumetanide have significant anxiolytic effects in
the conditioned models of anxiety (contextual fear-conditioning,
fear-potentiated startle) but not in the unconditioned models of
anxiety (elevated plus maze, open-field test). Since only single
doses furosemide and bumetanide were tested in each of the
models, we can not exclude the possibility that these drugs would
also show anxiolytic effects in the unconditioned models of anxiety
at higher doses. In view of this possibility, our data here only
supports the conclusion that these drugs are more potently
anxiolytic in conditioned models of anxiety than they are in
unconditioned models. Indeed, there does appear to be a small
effect of bumetanide in the open-field test, although it is not a
statistically significant effect. Further experiments, using higher
doses of furosemide and bumetanide, would be required to
determine whether or not these compounds are specifically
anxiolytic only for conditioned anxiety in rat models.
Figure 1. Contextual Fear-Conditioning Results. Percentage of
time during the contextual fear-conditioning test period during which
rats were freezing, following intravenous injections of vehicle (N=8),
bumetanide (N=8), and furosemide (N=8). Note: Error bars indicate
standard errors.
doi:10.1371/journal.pone.0035417.g001
Loop Diuretics Have Anxiolytic Effects
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35417Bumetanide and furosemide both have greater affinity for
NKCC1 over KCC2, and bumetanide has a very low affinity for
KCC2 [10]. In view of this consideration, it seems more probable
that these drugs mediate their anxiolytic effects through their
antagonism of NKCC1 rather than KCC2, since it might
otherwise be expected that bumetanide would be ineffective.
However, dose response studies of the efficacies of furosemide and
bumetanide in these anxiety models would be required to quantify
their relative potencies for mediating anxiolytic effects, and thus
necessary for providing more conclusive evidence of the specific
cation-chloride cotransporter involved. In addition to their
antagonism of NKCC1 and KCC2, it is always possible that
furosemide and bumetanide might affect other ion channels and
transporters in brain that could play a role in their anxiolytic
effects. For example, high concentrations of these drugs in other
tissues have been found to inhibit Cl
2/HCO3
2-exchange and
some types of Cl
2 channels [32,33]. However, the currently
available data suggests that these drugs have far greater affinity for
NKCC1 and KCC2 over these other putative targets, making such
alternative mechanisms less likely [10].
The rationale motivating the work here was that since loop
diuretics are possibly both antiepileptic and GABAA modulating,
then they might also be anxiolytic similar to other GABAA
modulating antiepileptic drugs. However, the actual mechanisms
through which chloride-cotransport antagonism might mediate the
anxiolytic effects observed here remain unknown. Indeed, one
possibility is that these medications increase the transmembrane
chloride gradients of neurons, which would increase hyperpolar-
ization occurring with GABAA receptor activation-related chloride
channel opening [11,13]. Increasing GABAA mediated inhibition
is also thought to be the mechanism through which benzodiaz-
epines mediate their anxiolytic effects [8]. However, antagonism of
the cation-chloride cotransporters with loop diuretics also mediate
a number of other important CNS effects, such as changes in cell
volumes and extracellular ion concentrations, that can significantly
influence the synchronization of neuronal firing activity
[16,31,34]. One possible concern regarding the interpretation of
our results is that the anxiolytic effects observed here might have
been the result from some systemic effect of diureses, rather than
from a CNS-specific pharmacological action of the loop diuretics
on neuronal and glial chloride-cotransporters. We feel this
possibility is an unlikely explanation for our observations, since
then, one might have expected to observe a similar anxiolytic
effect in all four of the models tested. This possibility could be
more definitively tested, for example, by repeating the experiments
described here with other diuretics that have no affinity for the
cation-chloride cotransporters. Further work will be needed to
determine the specific mechanisms by which chloride-cotransport
antagonism leads to the observed anxiolytic effect.
The doses of furosemide and bumetanide used here to elicit
anxiolytic effects in rats are large by comparison to their standard
doses when used clinically as diuretics for humans. In order to
translate the doses used here in the rats into ones that might be
anxiolytic in humans, it is important to note that loop diuretics are
metabolized much more rapidly and efficiently in rats than they
are in the humans [35,36]. Furosemide is 230 times less potently
diuretic in rats than in humans, with a half-life of 11 minutes in
rats compared with approximately 2 hours in humans [35].
Bumetanide is proportionally even less potent than furosemide
between rats and humans [36]. This suggests that, if loop diuretics
are indeed anxiolytic in humans, then much smaller doses than
used here would be required to achieve a therapeutic effect. Such a
species-specific difference in the therapeutic effects of loop
diuretics has been observed in studies of their antiepileptic
properties in rats and humans. Large doses, similar to the ones
used here, are required to suppress seizure activity in rats [9,31],
whereas standard clinical doses are sufficient to reduce seizure
activity in humans [15,16]. This suggests that, if loop diuretics are
indeed anxiolytic in humans, then standard clinical doses of
bumetanide (0.5–1.0 mg/dose) and furosemide (20–40 mg/dose)
might be sufficient to elicit anxiolytic effects in the humans. In
humans, oral doses of bumetanide and furosemide are quickly
absorbed and have good bioavailability [37].
Further work will also be needed to determine whether NKCC1
antagonists have anxiolytic effects in humans and, if so, which
Figure 2. Fear-Potentiated Startle Test Results. Startle amplitudes
for rats receiving intravenous injections of vehicle (N=7), rats receiving
furosemide (N=8), and rats receiving bumetanide (N=8). (A) Percent
amount of fear-potentiated startle, and (B) amplitude of startle to the
noise alone. Note: Error bars indicate standard errors.
doi:10.1371/journal.pone.0035417.g002
Table 1. Elevated Plus Maze Results.
Vehicle
Mean (SE)
Furosemide
Mean (SE)
Bumetanide
Mean (SE)
Closed Arm
Entries
6.13 (0.69) 5.25 (0.59) 5.13 (0.40)
Time Spent
in Open
58.13 (8.65) 56.25 (6.51) 68.75 (11.30)
Trips Down
Open Arms
0.50 (0.27) 0.63 (0.32) 0.88 (0.35)
doi:10.1371/journal.pone.0035417.t001
Loop Diuretics Have Anxiolytic Effects
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35417anxiety disorders are improved by these agents. Although the
results of this study suggest that NKCC1 antagonism might
improve disorders where conditioned anxiety plays an important
role, such as PTSD, and not disorders marked by unconditioned
anxiety, such as GAD, the available literature suggests that this
may not be the case (see Table 3). For example, benzodiazepines,
which reliably demonstrate therapeutic effects in the tests of
conditioned anxiety (contextual fear conditioning and fear-
potentiated startle), do not have a therapeutic effect on the
specific symptoms of PTSD, though they improve non-specific
anxiety in PTSD patients [8]. The effects of NKCC1 antagonists
on the four anxiety tests studied are unlike those of any of the
major classes of medications with anxiolytic effects in humans
(benzodiazepines, tricyclic antidepressants, SSRIs, SNRIs, and
5HT1A agonists), in that they appear to be specific to the
conditioned models (see Table 3). Nonetheless, positive effects on
these tests reliably predict some type of therapeutic anxiolytic
effects in humans [38]. As such, this study provides some evidence
for a new mechanism of anxiety and class of medications with
potential for treating anxiety disorders.
If chloride-cotransporter antagonists are effective in humans as
predicted by these animal models, they would be mediating their
therapeutic effects through a unique mechanism and molecular
target, and potentially have certain advantages over existing agents
in that they would be the only agents with immediate onset of
action (unlike SSRIs/SNRIs), and without the sedation, cognitive
impairment, and the abuse potential of benzodiazepines [6,39].
Furosemide has been safely used clinically since 1966 to treat
millions of patients for hypertension, edema, and heart failure, and
was ranked in 2008 as being the 17th most frequently prescribed
drug [40]. The need for improved anxiety therapeutics suggests it
may be worthwhile to carry out studies in humans with anxiety
disorders to determine the clinical utility of loop diuretics [5,6].
Materials and Methods
Ethics Statement
All procedures were performed in accordance with the
University of Lethbridge Animal Care Committee guidelines,
which follow the standards set by the Canadian Council on
Animal Care. This study was conducted under a protocol titled:
‘‘Assessment of the Therapeutics Potential of Bumetanide and
Furosemide in Treatment of Addictions, PTSD, and Anxiety in
Rats, approved by UNIVERSITY OF LETHBRIDGE Animal
Welfare Committee (AWC). Protocol #0513.
Animal Handling and Drug Delivery
Ninety-six male, adult (3–4 months old) Long-Evans rats,
housed in the University of Lethbridge vivarium, were used for
these studies. Rat housing consisted of Plexiglas cages with sawdust
bedding shared with two or three individuals. The colony room
was temperature-controlled (20–21uC) with a 12 h light/12 h dark
Table 2. Open-Field Test Results.
Vehicle Mean (SE) Furosemide Mean (SE) Bumetanide Mean (SE)
Total Distance Travelled 1506.25 (341.20) 1550.88 (290.81) 2411.88 (359.52)
Time Spent Moving 138.90 (25.59) 150.53 (21.34) 206.65 (28.00)
Number of Rears 31.50 (5.37) 40.13 (6.15) 49.13 (7.95)
Time Spent Rearing 129.05 (29.34) 117.49 (26.31) 188.39 (37.26)
Distance Travelled Within Margin 926.50 (232.06) 970.5 (197.22) 1410.50 (179.20)
Time Spent Within Margin 468.88 (35.15) 423.48 (27.35) 447.84 (28.62)
Distance Travelled Within Center 579.63 (134.06) 580.25 (113.73) 1001.75 (202.74)
Time Spent Within Center 131.13 (35.15) 176.53 (27.35) 152.16 (28.62)
doi:10.1371/journal.pone.0035417.t002
Table 3. Medications with Established Human Anxiolytic Effects.
Medication
Type
Contextual
Fear-
Conditioning
Fear-Potentiated
Startle
Elevated
Plus Maze
Open-Field
Test
Efficacy
in Human PD
Efficacy
in Human
GAD
Efficacy
in Human
PTSD
Efficacy
in Human
SAD
Loop
Diuretics
++ – – ????
Benzodiazepines ++ + + + /– + – +
Tricyclic
Antidepressants
+ –– ?+++ /– ?
SSRIs/SNRIs + – +/– – +++ * +
5HT1A
Agonists
? +/– +/– + – + ––
+At least one placebo-controlled study with the preponderance demonstrating an anxiolytic effect; -At least one placebo-controlled study with the preponderance not
finding an anxiolytic effect; +/2 At least one placebo-controlled study and the findings are equivocal and/or there is no clear preponderance of positive or negative
results; ? No placebo-controlled studies have been carried out. PD=Panic Disorder; GAD=Generalized Anxiety Disorder; PTSD=Post-Traumatic Stress Disorder; and
SAD=Social Anxiety Disorder. *Although there are a number of positive studies with SSRIs, the Institute of Medicine concluded that there was insufficient evidence to
support the efficacy of SSRIs in PTSD due to moderate effect sizes [8,27,28,30,35,38,46–52].
doi:10.1371/journal.pone.0035417.t003
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ad libitum. Seventy-two hours prior to the experiment, rats were
anaesthetized with isoflurane, and a cannula was implanted into
the right external jugular vein of each rat for the purpose of
administration of drugs [41]. Rats were thereafter kept in
independent cages, and the cannulas were flushed daily to ensure
patency. Bumetanide and furosemide were dissolved in DMSO
(vehicle), and all drugs were administered I.V. via a cannulated
jugular vein. Test drugs were administered 30 min prior to testing.
All behavioural testing was conducted during the light cycle
(7:00 am–7:00 pm). Testing occurred between the hours of
9:00 am and 3:00 pm. Different, randomly selected rats were
used for each group (i.e. no rat was retested in more than one
group). All testing was done under ambient room light.
Contextual Fear-Conditioning
Contextual Fear-Conditioning Contextual Fear-Conditioning,
following a previously described standard protocol, was performed
on 24 rats [42]. The testing chamber consisted of a rectangular
box (40 cm656 cm628 cm) with a stainless steel rod floor. All
aspects of the timing of events were under microcomputer control
(MedPC, MedAssociates Inc, Vermont, USA). Measurement of
freezing was accomplished through an overhead video camera
connected to a microcomputer and was automatically scored using
a specialty piece of software, FreezeFrame. In Phase 1, rats were
placed individually into the chambers for 5 minutes. Phase 2
occurred 24 hr later, when again rats were placed individually into
the same chambers, they received an immediate (within 3 s of
being placed into the chamber) foot shock (1 mA for 2 s). Thirty
seconds later they were removed from the chambers. During phase
3, 24 hr later, the rats were returned to the chambers for 5 min.
This session was video recorded and the amount of time spent
freezing was assessed using FreezeFrame software. Freezing was
defined as the total lack of body movement except for movement
related to respiration. The percentage time spent freezing during
each minute was entered into Excel spreadsheets and was analyzed
using SPSS statistical software. One-way analysis of variance
(ANOVA) was used to evaluate treatment effects.
Fear-Potentiated Startle
A Fear-Potentiated Startle protocol, following a previously
described protocol, was used to test 23 rats [43]. Animals were
trained and tested in four identical stabilimeter devices (Med-
Associates). Each rat was placed in a small Plexiglas cylinder. The
floor of each stabilimeter consisted of four 6-mm-diameter stainless
steel bars spaced 18 mm apart through which shock can be
delivered. Cylinder movements result in displacement of an
accelerometer where the resultant voltage is proportional to the
velocity of the cage displacement. Startle amplitude was defined as
the maximum accelerometer voltage that occurs during the first
0.25 sec after the startle stimulus was delivered. The analog output
of the accelerometer was amplified, digitized on a scale of 0–
4096 units and stored on a microcomputer. Each stabilimeter was
enclosedinaventilated,light-,andsound-attenuatingbox.Allsound
levelmeasurementsweremadewithaPrecisionSoundLevelMeter.
The noise of a ventilating fan attached to a sidewall of each wooden
boxproducesanoverallbackgroundnoiselevelof64 dB.Thestartle
stimulus was a 50 ms burst of white noise (5 ms rise–decay time)
generated by a white noise generator. The visual conditioned
stimulus was the illumination of a light bulb adjacent to the white
noise source. The unconditioned stimulus was a 0.6 mA foot shock
with duration of 0.5 s, generated by four constant-current shockers
locatedoutsidethechamber.Thepresentationandsequencingofall
stimuli were controlled by computer. FPS procedures consist of
5 daysoftesting;duringdays 1and2baselinestartleresponseswere
collected, days 3 and 4 light/shock pairings were delivered, day 5
testing for fear potentiated startle was conducted. Animals received
treatment with compound or vehicle on days 3, 4, and 5.
Matching. On days 1 and 2 rats were placed individually into
the Plexiglas cylinders and 3 min later presented with 30 startle
stimuliata 30 sec interstimulus interval. Anintensityof105 dB was
used.Themeanstartleamplitude acrossthe30startlestimulionthe
seconddaywasusedtoassignratsintotreatmentgroupswithsimilar
means.
Training. On days 3 and 4, rats were placed individually into
thePlexiglascylinders.Duringthefirst3 mininthechambertherats
wereallowedtoacclimatethen10CS-shockpairingsweredelivered.
The shock was delivered during the last 0.5 sec of the 3.7 sec CSsat
an average intertrial interval of 4 min (range, 3–5 min).
Testing. On the 5th day, rats were placed in the same startle
boxes where they were trained and after 3 min acclimation were
presented with 18 startle-eliciting stimuli (all at 105 dB). These
initial startle stimuli were used to again habituate the rats to the
acoustic startle stimuli. Thirty seconds after the last of these stimuli,
each animal receives 60 startle stimuli with half of the stimuli
presented alone (startle alone trials) and the other half presented
3.2 sec after the onset of the 3.7 sec CS (CS-startle trials). All startle
stimuli were presented at a mean 30 sec interstimulus interval,
randomly varying between 20 and 40 sec. Data were entered into
Excel spreadsheets and SPSSfor data analysis. Independent sample
t-tests are used to compare each treatment groups.
Elevated Plus Maze
AnElevatedPluseMazeprotocolwasusedtotest24rats[44].The
elevatedplusmazeconsistedoftwoopposingopenarms,50610 cm,
crossedwithtwoopposingenclosedarmsofthesamedimensionsbut
with walls 40 cm high. Each of the four arms was connected to one
side of a central square (10610 cm) giving the apparatus a plus-sign
appearance. The maze was elevated 50 cm above the floor in a
normallyilluminatedroom.Theratswereplacedindividuallyonthe
centralsquareoftheplusmazefacinganenclosedarm.Theentire3-
minsessionwasvideotapedandlaterscored.Thetimespentandthe
numberofentriesintotheopenandclosedarms,andthenumberof
trips made to at least the mid point down the open arms were
recorded.Anarmentrywasdefinedasplacementofallfourpawsonto
thesurfaceofthearm.Thetreatmentgroupswerecomparedontime
intheopen,closedarmentries,andtripstoatleastthemidpointdown
openarms with ANOVA.
Open-Field Test
Twenty-four rats underwent a standard Open-Field Test,
following a previously published protocol [45]. The open field
consisted of a latex-painted, circular wooden table, 155 cm in
diameter, raised 64 cm above the floor. To avoid scented residue
confounds, a ball bearing base allowed the table to be rotated
betweentrials.Thetablewasalsowipeddownwithsoapywaterafter
each trial. The table was located in a large room, painted white,
which contained several visual cues including light switches,
electrical outlets, a paper towel dispenser, a door, and two posters.
A ceiling-mounted, wide-angle lens video camera recorded each
trial in Standard Play format onto Mini Digital Videocassettes for
later analysis. During open field sessions, each rat was brought into
the testing room from its home cage and placed in the center of the
openfield, awayfrom the edges ofthe table to avoid the influence of
pointofentryonlocationpreference.Theexperimenterthenleftthe
room and initiated video recording. Sessions lasted 10 min, after
which the rat was removed from the table and returned to its home
cage. To examine the amount of time the rats spend in the various
Loop Diuretics Have Anxiolytic Effects
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the position of the rat on the Table into a series of Cartesian
coordinatessampledatarateof30 Hz.Customsoftwaredividedthe
openfieldTableintofourquadrants,andusedtheAccuTrakoutput
coordinates to determine the amount of time the rat spent in each
quadrant over the course of the trial. Time accrued within these
quadrants was measured as a sum for the entire 30-min trial, and as
experimenter-assigned 3-min bins, for a total of 10 time-bins.
Rearing, distance travelled, and time spent in field regions were
compared across treatment groups with ANOVA.
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